URGN
UroGenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The supported bull case is that UroGen now has two meaningful value drivers at once: ZUSDURI reimbursement friction improved after the January 1, 2026 J-code effective date, and UGN-103 has a defined regulatory path after the UTOPIA data. If launch metrics keep compounding and the NDA timeline holds, the stock has room to move toward a more development-plus-commercial multiple.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.4.
What can break
Cash, cash equivalents, and marketable securities were $120.5 million at December 31, 2025, while net loss was $153.5 million for 2025, keeping funding and cash-burn monitoring important.
Momentum
92
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $33.00 · Bear $16.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $35.63
Why
Momentum92 · Δ7d -4.4
Value41 · Δ7d +0.0
Sentiment44 · Δ7d +10.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
-2.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
44
33% active weight
Current posture
7d trendImproving
Δ7d
+10.5
Δ21d
+17.1
Why this grade
Composite grade B. Momentum 91.5 / Value 41.1 / Sentiment 43.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.29B
Beta
1.35
Shares Out
46.81M
P/E (TTM) · Derived
-8.7
P/S (TTM)
10.73
P/FCF (TTM) · Derived
-10.07
Rev YoY
+9.0%
EPS YoY
-26.3%
Gross Margin
+88.0%
Op Margin
-138.2%
Net Debt
-$112.61M
Current Ratio
3.99
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology